Prostate Cancer Inhibited by Compound against "Undruggable" Target

Scientists at New York University (NYU) and the New York University School of Medicine have used computer simulation tools to develop a new type of compound that blocks the interaction of proteins involved in driving drug-resistant prostate cancer. Rather than target the androgen receptor (AR), which is the main therapeutic target for prostate cancer, the new compound is designed to block the interaction between two proteins in the Wnt signaling pathway, which is commonly mutated in tumors from